HB 2883 would create a statewide directory for ENDS products—electronic nicotine delivery systems such as vapes, e-liquids, pods, cartridges, and disposable devices—and prohibit retail sale in West Virginia of any ENDS product not listed in that directory. To be listed, manufacturers would have to certify each product annually, pay a $100 fee per product, and provide documentation showing the product has FDA marketing authorization, a pending timely filed premarket tobacco product application, or a qualifying stayed/rescinded/vacated denial order. The bill also requires manufacturers to report material changes, designate an in-state agent for service of process if they are not registered in West Virginia, and, for foreign manufacturers, ensure importers also appoint agents.
The bill gives the Alcohol Beverage Control Administration Commissioner authority to maintain and publish the directory, update it monthly, issue notices before removal, and enforce compliance through unannounced inspections, seizures, forfeiture, destruction of noncompliant products, and civil penalties. Retailers, wholesalers, distributors, and importers would face escalating fines for selling unlisted products, while manufacturers could face a $10,000 civil penalty per product and misdemeanor liability for false statements. The bill also directs collected fees and penalties to administration and enforcement and requires annual reporting to the Legislature.
Its impact on state law would be to add a new Article 9H to the West Virginia Code governing ENDS product sales and enforcement. It would effectively tie lawful retail sale in the state to FDA-related product status and a state certification process, creating a new regulatory gatekeeping system for tobacco-nicotine vapor products. The bill would also expand enforcement powers for the commissioner, the Department of Revenue, the Attorney General, and state and local law enforcement, while creating new compliance obligations for manufacturers, importers, wholesalers, distributors, and retailers.
The overall sentiment reflected in the bill text is regulatory and enforcement-oriented, with the stated purpose of controlling the retail market for ENDS products and limiting sales to products that have gone through or are undergoing FDA review. Because there are no committee transcripts or recorded votes provided, there is no documented floor or committee debate to indicate broader support or opposition. Based on the structure of the bill, it appears designed to strengthen oversight and reduce the availability of unauthorized vape products rather than to expand consumer access.
The main points of contention likely center on the burden the bill places on manufacturers and retailers, especially smaller businesses and out-of-state or foreign manufacturers that would need to navigate certification, fees, agent designation, and compliance checks. Another likely issue is the bill’s reliance on FDA authorization status, which could remove many products from the market and expose inventory to seizure after short transition periods. Supporters would likely emphasize youth access prevention, product safety, and market accountability, while critics would likely focus on regulatory costs, supply disruption, and the risk of penalizing businesses for products still under federal review.
HB 2883 would add a new state regulatory framework for ENDS products by creating a public directory, conditioning lawful sale on inclusion in that directory, and assigning enforcement authority to the Alcohol Beverage Control Administration Commissioner. It would impose new certification, fee, notice, agent-for-service, inspection, reporting, and penalty requirements on manufacturers, importers, wholesalers, distributors, and retailers, while authorizing seizure and destruction of nonlisted products and civil and criminal penalties for violations.
No committee transcript or vote record is provided, so there is no direct evidence of legislative debate or recorded support/opposition. From the bill’s text, the measure is clearly enforcement-heavy and aimed at restricting the retail sale of ENDS products to those meeting FDA-related criteria, suggesting a generally restrictive, public-health-oriented approach rather than a permissive one.
Likely points of contention include the compliance burden on retailers and manufacturers, the $100-per-product annual certification fee, the $10,000-per-product manufacturer penalty, and the bill’s reliance on FDA marketing authorization or pending applications as the basis for state market access. Out-of-state and foreign manufacturers may object to the required in-state agent designation and the risk of product removal, while supporters would likely argue the directory is needed to curb unauthorized vape sales and improve enforcement against noncompliant products.